Artificial Intelligence in Hepatocellular Carcinoma Diagnosis and Treatment Decisions

doi:10.3877/cma.j.issn.2095-5782.2025.04.016

Abstract

Abstract:

Hepatocellular carcinoma (HCC) ranks third in global cancer mortality, with a 5-year survival rate below 20%, making its diagnosis and treatment a global medical priority. Artificial intelligence (AI), particularly machine learning and deep learning, has advanced rapidly in medical applications. AI models integrate medical imaging and clinical data to extract and analyze features from radiological and pathological images, enabling rapid, non-invasive HCC diagnosis. Additionally, AI supports non-invasive pathological assessments and prognostic predictions using pre-treatment clinical data. These technologies aid treatment decisions and optimize therapies, potentially improving patient outcomes.

Key words: Hepatocellular Carcinoma, Artificial Intelligence, Imaging, Diagnosis, Treatment Decision

Qiangqiang Xia, Xing Li, Lizhou Wang. Artificial Intelligence in Hepatocellular Carcinoma Diagnosis and Treatment Decisions[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2025, 13(04): 373-377.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2025.04.016

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2025/V13/I04/373

References 43

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]	Chon Y E, Jeong S W, Jun D W. Hepatocellular carcinoma statistics in South Korea[J]. Clin Mol Hepatol, 2021, 27(3): 512-514.
[3]	中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 协和医学杂志, 2024, 15(03): 532-559.
[4]	刘金明, 吴嘉艺, 刘安然, 等. 基于深度学习方法的肝癌伴胆道癌栓患者的术前诊断(英文)[J]. 中国科学技术大学学报, 2022, 52(12): 50-60,72.
[5]	Singal A G, Mukherjee A, Elmunzer B J, et al. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma[J]. Am J Gastroenterol, 2013, 108(11): 1723-1730.
[6]	Currie G, Hawk K E, Rohren E, et al. Machine Learning and Deep Learning in Medical Imaging: Intelligent Imaging[J]. J Med Imaging Radiat Sci, 2019, 50(4): 477-487.
[7]	祁亮, 沈洁. 机器学习在肝癌诊疗领域的应用进展[J]. 癌症进展, 2019, 17(05): 519-25.
[8]	Heimbach J K, Kulik L M, Finn R S, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380.
[9]	Yu N C, Chaudhari V, Raman S S, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2011, 9(2): 161-167.
[10]	Hwang Y N, Lee J H, Kim G Y, et al. Classification of focal liver lesions on ultrasound images by extracting hybrid textural features and using an artificial neural network[J]. Biomed Mater Eng, 2015, 26 Suppl 1: S1599-611.
[11]	Yang Q, Wei J, Hao X, et al. Improving B-mode ultrasound diagnostic performance for focal liver lesions using deep learning: A multicentre study[J]. EBioMedicine, 2020, 56: 102777.
[12]	Guo L H, Wang D, Qian Y Y, et al. A two-stage multi-view learning framework based computer-aided diagnosis of liver tumors with contrast enhanced ultrasound images[J]. Clin Hemorheol Microcirc, 2018, 69(3): 343-354.
[13]	Oestmann P M, Wang C J, Savic L J, et al. Deep learning-assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma(HCC)versus non-HCC on contrast-enhanced MRI of the liver[J]. Eur Radiol, 2021, 31(7): 4981-4990.
[14]	Gao R, Zhao S, Aishanjiang K, et al. Deep learning for differential diagnosis of malignant hepatic tumors based on multi-phase contrast-enhanced CT and clinical data[J]. J Hematol Oncol, 2021, 14(1): 154.
[15]	Zhen S H, Cheng M, Tao Y B, et al. Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data[J]. Front Oncol, 2020, 10: 680.
[16]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.[J]. J Hepatol, 2018, 69(1): 182-236.
[17]	Calderaro J, Ziiol M, Paradis V, et al. Molecular and histological correlations in liver cancer[J]. J Hepatol, 2019, 71(3): 616-630.
[18]	Wang R, He Y, Yao C, et al. Classification and Segmentation of Hyperspectral Data of Hepatocellular Carcinoma Samples Using 1-D Convolutional Neural Network[J]. Cytometry A, 2020, 97(1): 31-38.
[19]	Liao H, Long Y, Han R, et al. Deep learning-based classification and mutation prediction from histopathological images of hepatocellular carcinoma[J]. Clin Transl Med, 2020, 10(2): e102.
[20]	Lal S, Das D, Alabhya K, et al. NucleiSegNet: Robust deep learning architecture for the nuclei segmentation of liver cancer histopathology images[J]. Comput Biol Med, 2021, 128: 104075.
[21]	Kiani A, Uyumazturk B, Rajpurkar P, et al. Impact of a deep learning assistant on the histopathologic classification of liver cancer[J]. NPJ Digit Med, 2020, 3: 23.
[22]	Yang J D, Heimbach J K. New advances in the diagnosis and management of hepatocellular carcinoma[J]. BMJ, 2020, 371: m3544.
[23]	Llovet J M, Kelley R K, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):6.
[24]	Wen N, Cai Y, Li F, et al. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update[J]. Bioscience trends, 2022, 16(1): 20-30.
[25]	Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure[J]. Hepatology, 1998, 28(5): 1241-1246.
[26]	Jia X, Sun Z, Mi Q, et al. A Multimodality-Contribution-Aware TripNet for Histologic Grading of Hepatocellular Carcinoma[J]. IEEE/ACM Trans Comput Biol Bioinform, 2022, 19(4): 2003-2016.
[27]	Zhou Q, Zhou Z, Chen C, et al. Grading of hepatocellular carcinoma using 3D SE-DenseNet in dynamic enhanced MR images[J]. Comput Biol Med, 2019, 107: 47-57.
[28]	Xiong Y, Cao P, Lei X, et al. Accurate prediction of microvascular invasion occurrence and effective prognostic estimation for patients with hepatocellular carcinoma after radical surgical treatment[J]. World J Surg Oncol, 2022, 20(1): 328.
[29]	Chong H H, Yang L, Sheng R F, et al. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma≤5 cm[J]. Eur Radiol, 2021, 31(7): 4824-4838.
[30]	Chen Z H, Zhang X P, Feng J K, et al. Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China[J]. HPB(Oxford), 2022, 24(7): 1063-1073.
[31]	Chen Z H, Zhang X P, Feng J K, et al. Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China[J]. Hepatol Int, 2021, 15(3): 642-650.
[32]	Han J, Li Z L, Xing H, et al. The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study[J]. HPB(Oxford), 2019, 21(8): 962-971.
[33]	Wang F, Chen Q, Chen Y, et al. A novel multimodal deep learning model for preoperative prediction of microvascular invasion and outcome in hepatocellular carcinoma[J]. Eur J Surg Oncol, 2023, 49(1): 156-164.
[34]	Yang Y, Zhou Y, Zhou C, et al. Deep learning radiomics based on contrast enhanced computed tomography predicts microvascular invasion and survival outcome in early stage hepatocellular carcinoma[J]. Eur J Surg Oncol, 2022, 48(5): 1068-1077.
[35]	Zandavi S M, Kim C, Goodwin T, et al. AI-powered prediction of HCC recurrence after surgical resection: Personalised intervention opportunities using patient-specific risk factors[J]. Liver Int, 2024, 44(10): 2724-2737.
[36]	Chen M, Kong C, Qiao E, et al. Multi-algorithms analysis for pre-treatment prediction of response to transarterial chemoembolization in hepatocellular carcinoma on multiphase MRI[J]. Insights Imaging, 2023, 14(1): 38.
[37]	Liu Z, Liu Y, Zhang W, et al. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study[J]. Hepatol Int, 2022, 16(3): 577-589.
[38]	Mehta N, Guy J, Frenette C T, et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study[J]. Clin Gastroenterol Hepatol, 2018, 16(6): 955-964.
[39]	He T, Fong J N, Moore L W, et al. An imageomics and multi-network based deep learning model for risk assessment of liver transplantation for hepatocellular cancer[J]. Comput Med Imaging Graph, 2021, 89: 101894.
[40]	Yang C, Tan J, Chen Y, et al. Prediction of late recurrence after curative-intent resection using MRI-measured spleen volume in patients with hepatocellular carcinoma and cirrhosis[J]. Insights Imaging, 2024, 15(1): 31.
[41]	Abajian A, Murali N, Savic L J, et al. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept[J]. J Vasc Interv Radiol, 2018, 29(6): 850-857.
[42]	严律南, 杨家印. 人工智能肝癌临床决策支持系统的开发、验证和应用价值[J]. 中国普外基础与临床杂志, 2020, 27(09): 1052-1056.
[43]	Hiraoka A, Kumada T, Tada T, et al. Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality[J]. Liver cancer, 2023, 12(6): 565-575.

Please choose a citation manager

Content to export